



Shilpa Medicare Limited

Corporate & Admin Office:

"Shilpa House", # 12-6-214/A-1, Hyderabad Road,
Raichur – 584 135, Karnataka, India
Tel: +91-8532-238704, Fax: +91-8532-238876
Email: info@vbshilpa.com, Web: www.vbshilpa.com
CIN: L85110KA1987PLC008739

Date: 4th June,2024

To,

Corporate Relationship Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400 001

National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor,
Plot No.C/1, G Block
Bandra Kurla Complex, Bandra (E)
Mumbai-400 051

Dear Sir/Madam,

Sub: Intimation U/R 30 of the SEBI(LODR) Regulations- Reg.

Ref: Stock Code: NSE: SHILPAMED/BSE-530549

Type IV DMF (Drug Master File) of recombinant Human Albumin 20%

This is to inform you that Shilpa Biologicals Pvt Ltd, a wholly owned subsidiary of the Company has filed its first Drug Master File of **recombinant Human Albumin 20% with USFDA.**

This novel recombinant has been developed and is a patented novel recombinant Human Albumin 20% process which is completely-Environment friendly, Consistent High-Quality product, Scalable to massive scales and is cost competitive.

Recombinant Human Albumin 20% targets to fulfil growing demand of human serum albumin to deliver current and growing market demand.

**With Regards,
For SHILPA MEDICARE LIMITED**

Ritu Tiwary
Company Secretary & Compliance Officer